Oct 18, 2023 / 12:00PM GMT
David Zaccardelli - Verona Pharma plc - President & CEO
I'm David Zaccardelli. And thank you very much for joining us today for a commercial and launch readiness update for ensifentrine for the treatment of COPD.
Today, we're going to review a number of items. First, I'm going to start with just a very brief introduction and overview just to level set today on ensifentrine, COPD. And then I'll turn over the meeting to Chris Martin and Dr. Rutland, which are going to walk through, from a clinician point of view, the impact of ensifentrine in the treatment of COPD. And then Chris will give a very comprehensive update on where we are for launch readiness for ensifentrine, followed by a Q&A with the Verona team, which is here today to answer your questions.
So with that, I just want to remind everyone, of course, we'll be making forward-looking statements during today's presentation. And please refer to all our filings for risk factors related to these forward-looking statements.
So Verona Pharma, as you know, has a very good history of execution in the past several years.
Verona Pharma PLC Investor Launch Update Transcript
Oct 18, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers